An Analysis on the Effect of Patient-controlled Analgesia Performed by Orthopaedic Department or Postoperative Pain Control after Shoulder and Elbow Surgery.
10.5397/cise.2015.18.4.237
- Author:
Jae Kwang YUM
;
Jin Hyok KIM
;
Kyung Hwan BOO
;
Soo Hyung AHN
- Publication Type:Original Article
- Keywords:
Patient-controlled analgesia;
Non-steroidal anti-inflammatory agents;
Oxycodone;
Ramosetron;
Pain measurement
- MeSH:
Analgesia;
Analgesia, Patient-Controlled*;
Anti-Inflammatory Agents, Non-Steroidal;
Elbow*;
Humans;
Incidence;
Orthopedics;
Oxycodone;
Pain Management;
Pain Measurement;
Pain, Postoperative*;
Passive Cutaneous Anaphylaxis;
Retrospective Studies;
Shoulder*
- From:Clinics in Shoulder and Elbow
2015;18(4):237-241
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: We investigated the effectiveness of pain management and the adverse events of intravenous (IV) patient-controlled analgesia (PCA) after orthopedic surgery. METHODS: From September 2014 and August 2015, we performed a retrospective analysis of 77 patients who underwent orthopedic surgery of the shoulder or the elbow in our hospital. The composition of the intravenous PCA administered to the patients was as follows: 250 mg of dexketoprofen trametamol, 70 mg of oxycodone, and 0.6 mg of ramosetron, which were made up to 79 ml of normal saline. We evaluated and statistically analyzed the difference in the visual analogue scale (VAS) scores for pain at immediate postoperation, at 24 hours of PCA, at 72 hours of PCA, and after discontinuation of PCA and in the incidence of adverse events. RESULTS: We found that VAS score decreased for 3 postoperative days and that with discontinuation of IV PCA a meaningful change in VAS score was no longer seen. Of the 77 patients, 22 presented with adverse events (28.6%). We terminated IV PCA temporarily in the 21 patients who presented with adverse events; we terminated analgesia permanently in one patient (1.2%). Consequently, 76 of 77 patients carried out IV PCA till the designated period. CONCLUSIONS: Intravenous PCA after orthopedic surgery of the shoulder or the elbow may be accompanied with adverse events. Careful assessment of the patient and treatment of the adverse outcomes are key to a successful maintenance of PCA and to a successful management of postoperative pain.
